Date: 2012-01-04
Type of information: Nomination
Compound:
Company: AM-Pharma (The Netherlands)
Therapeutic area: Inflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 2012, AM-Pharma , a biopharmaceutical company focused on the preclinical and clinical development of recombinant human alkaline phosphatase (AP) for treatment of acute kidney injury and inflammatory bowel diseases, announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board. Dr Greig served nearly three decades with pharmaceutical giant GlaxoSmithKline, most recentlyas President of SR One, GSK’s Corporate Venture Group. Prior to joining SR One, he served as President of GSK's Pharmaceuticals International from 2003 to 2008 and also served on the GSK Corporate Executive Team. Dr Greig originally joined GSK (then SmithKline & French) in 1980 in the Departments of Tumor and Cell Biology. In 1991, following the merger with Beecham, he was appointed Vice President, Project Management. From 1993 to 1996, he served as Vice President and Director of Advanced Technologies in Genetics with special responsibility for managing collaborations with The
Institute of Genomic Research and Human Genome Sciences. In 1996, Dr Greig joined SmithKline Beecham's European Pharmaceutical Operations as Vice President and Director of European Market Development, and was later appointed Managing Director and General Manager of SmithKline Beecham's UK Pharmaceuticals. Following the merger of SmithKline Beecham with GlaxoWellcome in 2000, he returned to the United States as Senior Vice
President for Worldwide Business Development.
At the same time, Eric Claassen will step down from the board. Eric Claassen has been chairman of AM-Pharma for more than 10 years and shepherded the company through its initial phase of development, leading to AM-Pharma’s D-round. This €29.2m round announced in September 2011 was the largest private financing round in the Netherlands for a biotech firm ever.
Financial terms:
Latest news:
